Why the study?
Primary breast angiosarcoma is a rare malignancy with difficult diagnosis, poor prognosis, and an uncertain role for adjuvant chemotherapy and/or radiotherapy following mastectomy.
Does tumor vascular embolization reduce surgical risk in a patient with hemorrhaging primary breast angiosarcoma?
Does tumor vascular embolization reduce surgical risk in a patient with hemorrhaging primary breast angiosarcoma?
Tumor vascular embolization may be a useful adjunct to reduce surgical risk in patients with hemorrhaging primary breast angiosarcoma prior to mastectomy.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to PBA in rapid adolescent breast masses; leaves open optimal adjuvant strategies in young patients.
Background: Primary breast angiosarcoma (PBA) is a rare sarcoma, accounting for only 0.04% of all breast malignancies, with a difficult diagnosis and a poor prognosis. Mastectomy is the standard treatment, and the role of adjuvant treatment (chemotherapy and/or radiotherapy following surgery) remains uncertain with very few studies. Case Presentation: We report the case of a 17-year-old female patient who presented with a right breast lump that had rapidly increased in size and was hemorrhaging. She was diagnosed with breast angiosarcoma by needle biopsy and pathological evaluation. However, the mass showed a quick tendency to bleed during biopsies. After that, we performed angiography and tumor vascular embolization. The patient underwent a mastectomy followed by adjuvant chemotherapy. Conclusion: Tumor vascular embolization reduced the surgical risk of PBA with hemorrhage complications. Postoperative therapeutic roles still need further exploration and verification.
No takes yet. Share an insight, caveat, or question.
He et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: